Rémy Kinj1, Pierre-Yves Bondiau1, Eric François2, Jean-Pierre Gérard1, Arash O Naghavi3, Axel Leysalle1, Emmanuel Chamorey4, Ludovic Evesque2, Bernard Padovani5, Antoine Ianessi6, Karen Benezery1, Jérôme Doyen7. 1. Department of Radiation Oncology, Centre Antoine-Lacassagne, Nice, France. 2. Department of Medical Oncology, Centre Antoine-Lacassagne, Nice, France. 3. H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. 4. Department of Statistics, Centre Antoine-Lacassagne, Nice, France. 5. Department of Radiology, Centre Hospitalo-Universitaire Louis Pasteur, Nice, France. 6. Department of Radiology, Centre Antoine-Lacassagne, Nice, France. 7. Department of Radiation Oncology, Centre Antoine-Lacassagne, Nice, France; University of Nice Sophia-Antipolis, Nice, France. Electronic address: jerome.doyen@nice.unicancer.fr.
Abstract
INTRODUCTION: Patients with metastatic colorectal cancer (CRC) may present with oligometastatic lung lesions for which stereotactic ablative radiotherapy (SABR) can be utilized. This study aims to report efficacy and prognostic factors associated with colorectal lung metastases treated with SABR. MATERIAL AND METHODS: This is a retrospective study including patients who presented with lung oligometastasis from CRC treated with SABR from September 2007 to November 2014. RESULTS: We identified 53 oligometastatic patients with 87 lung lesions. The median prescription dose was 60 Gy in 3 fractions (median biological effective dose of 180 Gy). The median follow up was 33 months. The 1- and 2-year local control, metastasis-free survival, and overall survival were 79.8% and 78.2%, 29.2% and 16.2%, and 83.8% and 69.3%, respectively. On multivariate analysis, rectal primary site (P = .001) and > 2 metastases (P = .02) were significantly associated with a lower local control rate. Rectal lesions were associated with higher radiation dose (169.3 Gy vs. 153.3 Gy; P = .01) and higher rate of KRAS mutations (73.3% vs. 40.4%; P = .02). KRAS mutation did not predict for local control, but predicted for a 1-year metastasis-free survival detriment (0% vs. 37.5%; P = .04), when compared with KRAS wild-type. On multivariate analysis, there is an overall survival detriment associated with gross tumor volume ≥ 3266 mm3 (P = .03) and > 2 metastases (P = .04). CONCLUSION: In CRC, oligometastatic lung lesions treated with SABR had a worse outcome in patients presenting with a rectal primary, > 2 metastases, or treated with a larger gross tumor volume. More aggressive treatment may be considered in this subset of patients to improve outcome.
INTRODUCTION:Patients with metastatic colorectal cancer (CRC) may present with oligometastatic lung lesions for which stereotactic ablative radiotherapy (SABR) can be utilized. This study aims to report efficacy and prognostic factors associated with colorectal lung metastases treated with SABR. MATERIAL AND METHODS: This is a retrospective study including patients who presented with lung oligometastasis from CRC treated with SABR from September 2007 to November 2014. RESULTS: We identified 53 oligometastatic patients with 87 lung lesions. The median prescription dose was 60 Gy in 3 fractions (median biological effective dose of 180 Gy). The median follow up was 33 months. The 1- and 2-year local control, metastasis-free survival, and overall survival were 79.8% and 78.2%, 29.2% and 16.2%, and 83.8% and 69.3%, respectively. On multivariate analysis, rectal primary site (P = .001) and > 2 metastases (P = .02) were significantly associated with a lower local control rate. Rectal lesions were associated with higher radiation dose (169.3 Gy vs. 153.3 Gy; P = .01) and higher rate of KRAS mutations (73.3% vs. 40.4%; P = .02). KRAS mutation did not predict for local control, but predicted for a 1-year metastasis-free survival detriment (0% vs. 37.5%; P = .04), when compared with KRAS wild-type. On multivariate analysis, there is an overall survival detriment associated with gross tumor volume ≥ 3266 mm3 (P = .03) and > 2 metastases (P = .04). CONCLUSION: In CRC, oligometastatic lung lesions treated with SABR had a worse outcome in patients presenting with a rectal primary, > 2 metastases, or treated with a larger gross tumor volume. More aggressive treatment may be considered in this subset of patients to improve outcome.
Authors: Christopher Cao; Daniel Wang; David H Tian; Ashley Wilson-Smith; James Huang; Andreas Rimner Journal: J Thorac Dis Date: 2019-12 Impact factor: 2.895
Authors: Kamran A Ahmed; Jacob G Scott; John A Arrington; Arash O Naghavi; G Daniel Grass; Bradford A Perez; Jimmy J Caudell; Anders E Berglund; Eric A Welsh; Steven A Eschrich; Thomas J Dilling; Javier F Torres-Roca Journal: J Thorac Oncol Date: 2018-05-05 Impact factor: 20.121
Authors: Hoon Sik Choi; Bae Kwon Jeong; Ki Mun Kang; Hojin Jeong; Jin Ho Song; In Bong Ha; Oh-Young Kwon Journal: Cancer Res Treat Date: 2020-07-21 Impact factor: 4.679